Loading organizations...

Clinical-stage neurotechnology for treating neurodegenerative diseases.
Cognito Therapeutics develops non-invasive neuromodulation therapies for neurodegenerative diseases, focusing initially on Alzheimer's. The company's investigational therapeutic aims to slow or stop cognitive decline and preserve brain volume through its proprietary technology, which has received FDA Breakthrough Device Designation. This approach leverages specific external stimuli to influence brain activity, offering a novel method for disease modification.
The company was founded in 2016 by scientific co-founders Professors Li-Huei Tsai and Ed Boyden, both renowned researchers from MIT. Their foundational insight stemmed from pioneering optogenetics research, which demonstrated the potential to non-invasively modulate neural oscillations and improve brain function, laying the groundwork for Cognito's therapeutic platform.
Cognito Therapeutics primarily serves patients grappling with neurodegenerative conditions, with a clear focus on those living with Alzheimer's disease. The company's vision centers on transforming the treatment landscape by delivering clinically validated, non-invasive therapies that can improve cognitive performance and halt disease progression. It aims to meaningfully impact the health and well-being of patients requiring new solutions for these debilitating diseases.
Cognito Therapeutics has raised $283.0M across 3 funding rounds.
Cognito Therapeutics has raised $283.0M in total across 3 funding rounds.
Cognito Therapeutics is a late‑stage neurotechnology company developing a non‑invasive audiovisual neuromodulation therapy called Spectris that aims to evoke gamma‑frequency brain activity to slow brain atrophy and functional decline in Alzheimer’s disease and other neurodegenerative conditions[3][1]. Spectris is delivered as an at‑home headset that uses synchronized light and sound stimulation and has shown preservation of brain structure and slowing of cognitive/functional decline in feasibility and Phase 2 studies (OVERTURE), and the device has FDA Breakthrough Device designation for mild‑to‑moderate Alzheimer’s disease[3][4].
High‑Level Overview
Origin Story
Core Differentiators
Role in the Broader Tech and Biotech Landscape
Quick Take & Future Outlook
Cognito Therapeutics has raised $283.0M in total across 3 funding rounds.
Cognito Therapeutics's investors include IAG Capital Partners, Gerald Chan, Starbloom Capital, Apollo Health Ventures, Benvolio Group, New Vintage, Helen H. Liang, PhD, Scribble Ventures, Michael Ma, Ron Pragides, Alzheimer's Drug Discovery Foundation, WS Investment Company.
Cognito Therapeutics has raised $283.0M across 3 funding rounds. Most recently, it raised $105.0M Series C in March 2026.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Mar 5, 2026 | $105.0M Series C | IAG Capital Partners, Gerald Chan, Starbloom Capital | Apollo Health Ventures, Benvolio Group, New Vintage |
| Mar 1, 2023 | $73.0M Series B | Helen H. Liang, PhD | Scribble Ventures, Michael Ma, Ron Pragides, Alzheimer's Drug Discovery Foundation, IAG Capital Partners, Starbloom Capital, WS Investment Company |
| $105.0M Cognito Therapeutics raises $105M in series-c | IAG Capital Partners | Gerald Chan |